Lowest Price Guaranteed
Pages
234
Last Updated
June 2026
View Count
17641
1. PREFACE
1.1. Introduction
1.2. Market Share Insights
1.3. Key Market Insights
1.4. Report Coverage
1.5. Key Questions Answered
1.6. Chapter Outlines
2. RESEARCH METHODOLOGY
2.1. Chapter Overview
2.2. Research Assumptions
2.3. Database Building
2.3.1. Data Collection
2.3.2. Data Validation
2.3.3. Data Analysis
2.4. Project Methodology
2.4.1. Secondary Research
2.4.1.1. Annual Reports
2.4.1.2. Academic Research Papers
2.4.1.3. Company Websites
2.4.1.4. Investor Presentations
2.4.1.5. Regulatory Filings
2.4.1.6. White Papers
2.4.1.7. Industry Publications
2.4.1.8. Conferences and Seminars
2.4.1.9. Government Portals
2.4.1.10. Media and Press Releases
2.4.1.11. Newsletters
2.4.1.12. Industry Databases
2.4.1.13. Roots Proprietary Databases
2.4.1.14. Paid Databases and Sources
2.4.1.15. Social Media Portals
2.4.1.16. Other Secondary Sources
2.4.2. Primary Research
2.4.2.1. Introduction
2.4.2.2. Types
2.4.2.2.1. Qualitative
2.4.2.2.2. Quantitative
2.4.2.3. Advantages
2.4.2.4. Techniques
2.4.2.4.1. Interviews
2.4.2.4.2. Surveys
2.4.2.4.3. Focus Groups
2.4.2.4.4. Observational Research
2.4.2.4.5. Social Media Interactions
2.4.2.5. Stakeholders
2.4.2.5.1. Company Executives (CXOs)
2.4.2.5.2. Board of Directors
2.4.2.5.3. Company Presidents and Vice Presidents
2.4.2.5.4. Key Opinion Leaders
2.4.2.5.5. Research and Development Heads
2.4.2.5.6. Technical Experts
2.4.2.5.7. Subject Matter Experts
2.4.2.5.8. Scientists
2.4.2.5.9. Doctors and Other Hospitals
2.4.2.6. Ethics and Integrity
2.4.2.6.1. Research Ethics
2.4.2.6.2. Data Integrity
2.4.3. Analytical Tools and Databases
3. ECONOMIC AND OTHER PROJECT SPECIFIC CONSIDERATIONS
3.1. Forecast Methodology
3.1.1. Top-Down Approach
3.1.2. Bottom-Up Approach
3.1.3. Hybrid Approach
3.2. Market Assessment Framework
3.2.1. Total Addressable Market (TAM)
3.2.2. Serviceable Addressable Market (SAM)
3.2.3. Serviceable Obtainable Market (SOM)
3.2.4. Currently Acquired Market (CAM)
3.3. Forecasting Tools and Techniques
3.3.1. Qualitative Forecasting
3.3.2. Correlation
3.3.3. Regression
3.3.4. Time Series Analysis
3.3.5. Extrapolation
3.3.6. Convergence
3.3.7. Forecast Error Analysis
3.3.8. Data Visualization
3.3.9. Scenario Planning
3.3.10. Sensitivity Analysis
3.4. Key Considerations
3.4.1. Demographics
3.4.2. Market Access
3.4.3. Reimbursement Scenarios
3.4.4. Industry Consolidation
3.5. Robust Quality Control
3.6. Key Market Segmentations
3.7. Limitations
4. MACRO-ECONOMIC INDICATORS
4.1. Chapter Overview
4.2. Market Dynamics
4.2.1. Time Period
4.2.1.1. Historical Trends
4.2.1.2. Current and Forecasted Estimates
4.2.2. Currency Coverage
4.2.2.1. Overview of Major Currencies Affecting the Market
4.2.2.2. Impact of Currency Fluctuations on the Industry
4.2.3. Foreign Exchange Impact
4.2.3.1. Evaluation of Foreign Exchange Rates and Their Impact on Market
4.2.3.2. Strategies for Mitigating Foreign Exchange Risk
4.2.4. Recession
4.2.4.1. Historical Analysis of Past Recessions and Lessons Learnt
4.2.4.2. Assessment of Current Economic Conditions and Potential Impact on the Market
4.2.5. Inflation
4.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy
4.2.5.2. Potential Impact of Inflation on the Market Evolution
4.2.6. Interest Rates
4.2.6.1. Overview of Interest Rates and Their Impact on the Market
4.2.6.2. Strategies for Managing Interest Rate Risk
4.2.7. Commodity Flow Analysis
4.2.7.1. Type of Commodity
4.2.7.2. Origins and Destinations
4.2.7.3. Values and Weights
4.2.7.4. Modes of Transportation
4.2.8. Global Trade Dynamics
4.2.8.1. Import Scenario
4.2.8.2. Export Scenario
4.2.9. War Impact Analysis
4.2.9.1. Russian-Ukraine War
4.2.9.2. Israel-Hamas War
4.2.10. COVID Impact / Related Factors
4.2.10.1. Global Economic Impact
4.2.10.2. Industry-specific Impact
4.2.10.3. Government Response and Stimulus Measures
4.2.10.4. Future Outlook and Adaptation Strategies
4.2.11. Other Indicators
4.2.11.1. Fiscal Policy
4.2.11.2. Consumer Spending
4.2.11.3. Gross Domestic Product (GDP)
4.2.11.4. Employment
4.2.11.5. Taxes
4.2.11.6. R&D Innovation
4.2.11.7. Stock Market Performance
4.2.11.8. Supply Chain
4.2.11.9. Cross-Border Dynamics
5. EXECUTIVE SUMMARY
6. INTRODUCTION
6.1. Chapter Overview
6.2. Overview of Heart Failure
6.2.1. Target Addressable Market
6.2.2. Recent Trend and Future Outlook
6.2.3. Challenges Associated with KRAS
6.3. Future Perspective
7. COMPETITIVE LANDSCAPE
7.1. Chapter Overview
7.2. KRAS Providers: Overall Market Landscape
7.2.1. Analysis by Year of Establishment
7.2.2. Analysis by Company Size
7.2.3. Analysis by Location of Headquarters
7.2.4. KRAS Market: Overall Market Landscape
7.2.4.1. Analysis by Drug Class Type
7.2.4.2. Analysis by Administration Type
7.2.4.3. Analysis by Heart Failure Type
7.2.4.4. Analysis by Distribution Channel Type
7.2.4.5. Analysis by End User
8. COMPANY COMPETITIVENESS ANALYSIS
8.1. Chapter Overview
8.2. Assumptions and Key Parameters
8.3. Methodologies
8.4. Company Competitiveness Analysis: KRAS Providers
8.4.1. KRAS Providers Based in North America (Peer Group 1)
8.4.2. KRAS Providers Based in Europe (Peer Group 2)
8.4.3. KRAS Providers Based in Asia-Pacific (Peer Group 3)
8.4.4. KRAS Providers Based in Middle East and North Africa, and Latin America (Peer Group 4)
8.5. Key Findings
9. COMPANY PROFILES
9.1. Chapter Overview
9.2. Amgen
9.2.1. Company Overview
9.2.2. Financial Information
9.2.3. KRAS Pipeline
9.2.4. Recent Developments and Future Outlook
* Similar details are presented for other below mentioned companies based on information in the public domain
9.3. GlobeImmune
9.4. Jacobio Pharmaceuticals
9.5. Novartis
9.6. Onconova Therapeutics
9.7. Targovax
9.8. Verastem Oncology
10. SWOT ANALYSIS
11. MARKET IMPACT ANALYSIS
11.1. Chapter Overview
11.2. Market Drivers
11.3. Market Restraints
11.4. Market Opportunities
11.5. Market Challenges
11.6. Conclusion
12. PARTNERSHIPS AND COLLABORATIONS
12.1. Chapter Overview
12.2. Partnership Models
12.3. Orphan Drugs: Partnerships and Collaborations
12.3.1. Analysis by Year of Partnership
12.3.2. Analysis by Type of Partnership
12.3.3. Analysis by Year and Type of Partnership
12.3.4. Analysis by Type of Partner
12.3.5. Analysis by Location of Headquarters of Partner
12.3.6. Analysis by Type of Partnership and Location of Headquarters of Partner
12.3.7. Most Active Players: Analysis by Number of Partnerships
12.3.8. Regional Analysis
12.3.8.1. Intercontinental and Intracontinental Deals
12.3.8.2. Local and International Deals
13. FUNDING AND INVESTMENTS ANALYSIS
13.1. Funding Models
13.2. Orphan Drugs: Funding and Investments
13.2.1. Analysis by Year of Funding
13.2.2. Analysis of Funding Instances by Type of Funding
13.2.3. Analysis of Funding Instances by Year and Type of Funding
13.2.4. Analysis of Amount Invested by Type of Funding
13.2.5. Analysis of Funding Instances by Country
13.2.6. Most Active Players: Analysis by Amount Raised
13.3. Summary and Key Takeaways
14. KEY COMMERCIALIZATION STRATEGIES
14.1. Successful Drug Launch Strategy: ROOTS Framework
14.2. Successful Drug Launch Strategy: Product Differentiation
14.3. Commonly Adopted Commercialization Strategies based on the Development Stage of the Product
14.4. Key Commercialization Strategies Adopted by Companies Focused on RAS Targeting Therapies
14.4.1. Strategies Adopted Before Therapy Approval
14.5. Strategies Adopted During / Post Therapy Approval
14.6. Analysis by Ease of Implementation, Value Addition and Current Adoption (Harvey Ball Framework)
15. GLOBAL KRAS MARKET
15.1. Chapter Overview
15.2. Key Assumptions and Methodology
15.3. Trends Disruption Impacting Market
15.4. Global KRAS Market, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
15.5. Multivariate Scenario Analysis
15.5.1. Conservative Scenario
15.5.2. Optimistic Scenario
15.6. Key Market Segmentations
16. MARKET OPPORTUNITIES BASED ON TYPE OF DISEASE INDICATION
16.1. Chapter Overview
16.2. Key Assumptions and Methodology
16.3. Revenue Shift Analysis
16.4. Market Movement Analysis
16.5. Penetration-Growth (P-G) Matrix
16.6. KRAS Market for Acute Myeloid Leukemia: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
16.7. KRAS Market for Colorectal Cancer: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
16.8. KRAS Market for Cancer: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
16.9. KRAS Market for Head and Neck Cancer: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
16.10. KRAS Market for Non-Small Cell Lung Cancer: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
16.11. KRAS Market for Ovarian Cancer: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
16.12. KRAS Market for Pancreatic Cancer: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
16.13. KRAS Market for Phelan-McDermid Syndrome: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
16.14. KRAS Market for Skin Cancer: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
16.15. Data Triangulation and Validation
17. MARKET OPPORTUNITIES BASED ON TYPE OF MOLECULE
17.1. Chapter Overview
17.2. Key Assumptions and Methodology
17.3. Revenue Shift Analysis
17.4. Market Movement Analysis
17.5. Penetration-Growth (P-G) Matrix
17.6. KRAS Market for Small Molecules: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
17.7. KRAS Market for Biologics: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
17.8. Data Triangulation and Validation
18. MARKET OPPORTUNITIES BASED ON TYPE OF THERAPY
18.1. Chapter Overview
18.2. Key Assumptions and Methodology
18.3. Revenue Shift Analysis
18.4. Market Movement Analysis
18.5. Penetration-Growth (P-G) Matrix
18.6. KRAS Market for Monotherapy: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
18.7. KRAS Market for Combination Therapy: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
18.8. Data Triangulation and Validation
19. MARKET OPPORTUNITIES BASED ON TYPE OF THERAPEUTIC AREA
19.1. Chapter Overview
19.2. Key Assumptions and Methodology
19.3. Revenue Shift Analysis
19.4. Market Movement Analysis
19.5. Penetration-Growth (P-G) Matrix
19.6. KRAS Market for Oncological Disorders: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
19.7. KRAS Market for Genetic Disorders: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
19.8. Data Triangulation and Validation
20. MARKET OPPORTUNITIES BASED ON ROUTE OF ADMINISTRATION
20.1. Chapter Overview
20.2. Key Assumptions and Methodology
20.3. Revenue Shift Analysis
20.4. Market Movement Analysis
20.5. Penetration-Growth (P-G) Matrix
20.6. KRAS Market for Intravenous: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
20.7. KRAS Market for Intramuscular: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
20.8. KRAS Market for Intradermal: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
20.9. KRAS Market for Intraocular: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
20.10. KRAS Market for Intraperitoneal: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
20.11. KRAS Market for Oral: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
20.12. KRAS Market for Subcutaneous: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
20.13. Data Triangulation and Validation
21. MARKET OPPORTUNITIES BASED ON TYPE OF DEVELOPMENT PHASE
21.1. Chapter Overview
21.2. Key Assumptions and Methodology
21.3. Revenue Shift Analysis
21.4. Market Movement Analysis
21.5. Penetration-Growth (P-G) Matrix
21.6. KRAS Market for Phase I / II: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
21.7. KRAS Market for Phase III: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
21.8. KRAS Market for Approved: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
21.9. Data Triangulation and Validation
22. MARKET OPPORTUNITIES FOR KRAS IN NORTH AMERICA
22.1. Chapter Overview
22.2. Key Assumptions and Methodology
22.3. Revenue Shift Analysis
22.4. Market Movement Analysis
22.5. Penetration-Growth (P-G) Matrix
22.6. KRAS Market in North America: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
22.6.1. KRAS Market in the US: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
22.6.2. KRAS Market in Canada: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
22.6.3. KRAS Market in Mexico: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
22.7. Data Triangulation and Validation
23. MARKET OPPORTUNITIES FOR KRAS IN EUROPE
23.1. Chapter Overview
23.2. Key Assumptions and Methodology
23.3. Revenue Shift Analysis
23.4. Market Movement Analysis
23.5. Penetration-Growth (P-G) Matrix
23.6. KRAS Market in Europe: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
23.6.1. KRAS Market in Germany: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
23.6.2. KRAS Market in France: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
23.6.3. KRAS Market in Italy: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
23.6.4. KRAS Market in Spain: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
23.6.5. KRAS Market in the UK: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
23.6.6. KRAS Market in Rest of Europe: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
23.7. Data Triangulation and Validation
24. MARKET OPPORTUNITIES FOR KRAS IN ASIA-PACIFIC
24.1. Chapter Overview
24.2. Key Assumptions and Methodology
24.3. Revenue Shift Analysis
24.4. Market Movement Analysis
24.5. Penetration-Growth (P-G) Matrix
24.6. KRAS Market in Asia-Pacific: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
24.6.1. KRAS Market in China: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
24.6.2. KRAS Market in India: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
24.6.3. KRAS Market in Japan: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
24.6.4. KRAS Market in South Korea: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
24.6.5. KRAS Market in Rest of the Asia-Pacific: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
24.7. Data Triangulation and Validation
25. MARKET OPPORTUNITIES FOR KRAS IN MIDDLE EAST AND AFRICA (MEA)
25.1. Chapter Overview
25.2. Key Assumptions and Methodology
25.3. Revenue Shift Analysis
25.4. Market Movement Analysis
25.5. Penetration-Growth (P-G) Matrix
25.6. KRAS Market in Middle East and Africa (MEA): Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
25.6.1. KRAS Market in Egypt: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
25.6.2. KRAS Market in Saudi Arabia: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
25.6.3. KRAS Market in United Arab Emirates (UAE): Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
25.7. Data Triangulation and Validation
26. MARKET OPPORTUNITIES FOR KRAS IN LATIN AMERICA
26.1. Chapter Overview
26.2. Key Assumptions and Methodology
26.3. Revenue Shift Analysis
26.4. Market Movement Analysis
26.5. Penetration-Growth (P-G) Matrix
26.6. KRAS Market in Latin America: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
26.6.1. KRAS Market in Brazil: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
26.6.2. KRAS Market in Argentina: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
26.6.3. KRAS Market in Rest of the Latin America: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
26.7. Data Triangulation and Validation
27. APPENDIX 1: TABULATED DATA
28. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS
29. CUSTOMIZATION OPPORTUNITIES
30. ROOTS SUBSCRIPTION SERVICES
31. AUTHOR DETAIL
Figure 3.1 Approaches for Targeting Mutated RAS Gene
Figure 3.2 Notable Developments within the RAS Targeting Therapies Domain
Figure 3.3 Prominent Gene Driver related Mutations in RAS Mutated Cancers
Figure 3.4 Key Challenges Associated with Targeting and Treatment of RAS Mutated Cancers
Figure 3.5 Future Perspectives of RAS Targeting Therapies
Figure 4.1 RAS Targeting Therapies: Distribution by Phase of Development
Figure 4.2 RAS Targeting Therapies: Distribution by Route of Administration
Figure 4.3 RAS Targeting Therapies: Distribution by Line of Treatment and Type of Therapy
Figure 4.4 RAS Targeting Therapies: Distribution by Type of Molecule
Figure 4.5 RAS Targeting Therapies: Distribution by Phase of Development and Type of Molecule
Figure 4.6 RAS Targeting Therapies: Distribution by Type of Molecule and Route of Administration
Figure 4.7 RAS Targeting Therapies: Distribution by Target Gene and Target Indication
Figure 4.8 Most Active Players: Distribution by Number of Trials Registered
Figure 4.9 RAS Targeting Therapy Developers: Distribution by Year of Establishment
Figure 4.10 RAS Targeting Therapy Developers: Distribution by Company Size
Figure 4.11 RAS Targeting Therapy Developers: Distribution by Location of Headquarters
Figure 4.12 RAS Targeting Therapy Developers: Distribution by Geography
Figure 5.1 Clinical Trial Analysis: Cumulative Distribution of Trials by Trial Registration Year
Figure 5.2 Clinical Trial Analysis: Distribution by Type of Masking and Intervention Model Adopted
Figure 5.3 Clinical Trial Analysis: Distribution by Study Design and Trial Status
Figure 5.4 Clinical Trial Analysis: Distribution by Type of Sponsor
Figure 5.5 Most Active Players: Distribution by Number of Clinical Trials
Figure 5.6 Clinical Trial Analysis: Distribution by Trial Registration Year and Geography
Figure 5.7 Clinical Trial Analysis: Distribution by Target Indication
Figure 5.8 Clinical Trial Analysis: Distribution of Number of Trials by Geography
Figure 5.9 Clinical Trial Analysis: Distribution by Trial Registration Year and Enrolled Patients Population
Figure 5.10 Clinical Trial Analysis: Distribution by Geography, Patients Enrolled and Trial Status
Figure 5.11 Clinical Trial Analysis: Distribution by Patients Enrolled and Phase of Development
Figure 6.1 Product Competitiveness Analysis: North America Scenario
Figure 6.2 Product Competitiveness Analysis: Europe Scenario
Figure 6.3 Product Competitiveness Analysis: Asia-Pacific Scenario
Figure 7.1 Amgen: Financial Information
Figure 7.2 GlobeImmune: Financial Information
Figure 7.3 Jacobio Pharmaceuticals: Financial Information
Figure 7.4 Mirati Therapeutics: Financial Information
Figure 7.5 Novartis: Financial Information
Figure 7.6 Onconova Therapeutics: Financial Information
Figure 7.7 Targovax: Financial Information
Figure 7.8 Verastem Oncology: Financial Information
Figure 8.1 Publication Analysis: Distribution by Year of Publication
Figure 8.2 Publication Analysis: Distribution by Type of Publication
Figure 8.3 Publication Analysis: Distribution by Study Objective
Figure 8.4 Publication Analysis: Distribution by Emerging Focus Area
Figure 8.5 Publication Analysis: Distribution by Target Gene
Figure 8.6 Publication Analysis: Distribution by Target Therapeutic Area
Figure 8.7 Publication Analysis: Distribution by Target Indication
Figure 8.8 Publication Analysis: Distribution by Affiliation of First Author
Figure 8.9 Most Active Players: Distribution by Number of Publications
Figure 8.10 Key Journals: Distribution by Number of Publications
Figure 9.1 Partnerships and Collaborations: Distribution by Year of Partnership
Figure 9.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 9.3 Partnerships and Collaborations: Distribution by Type of Partner
Figure 9.4 Partnerships and Collaborations: Distribution by Type of Molecule
Figure 9.5 Most Active Players: Distribution by Number of Partnerships
Figure 9.6 Most Active Partners: Distribution by Number of Partnerships
Figure 9.7 Partnerships and Collaborations: Intercontinental and Intracontinental Agreements
Figure 10.1 Funding and Investment Analysis: Cumulative Year-wise Distribution by Amount Invested, 2016-2021
Figure 10.2 Funding and Investment Analysis: Distribution by Type of Funding
Figure 10.3 Funding and Investment Analysis: Distribution by Year and Type of Funding
Figure 10.4 Funding and Investment Analysis: Distribution by Year, Amount Invested and Type of Funding, 2016-2021 (USD Million)
Figure 10.5 Funding and Investment Analysis: Distribution of Total Amount Invested by Type of Funding (USD Million)
Figure 10.6 Key Investors: Distribution by Number of Funding Instances
Figure 10.7 Funding and Investment Analysis: Distribution of Amount Invested by Geography (USD Million)
Figure 11.1 Key Commercialization Strategies: Harvey Ball Analysis
Figure 11.2 Successful Drug Launch Strategy: ROOTS Framework
Figure 11.3 Historical Strategies Adopted by the Developer of LUMAKRAS™
Figure 11.4 Successful Drug Launch Strategy: Product Differentiation
Figure 11.5 Commonly Adopted Commercialization Strategies based on Development Stage of the Product
Figure 11.6 Harvey Ball Analysis: Commercialization Strategies Adopted by RAS Targeting Therapy Developers
Figure 12.1 RAS Targeting Therapies Market, 2021-2031 (USD Million)
Figure 12.2 RAS Targeting Therapies Market: Distribution by Type of Molecule / Drug Class (USD Million)
Figure 12.3 RAS Targeting Therapies Market: Distribution by Type of Therapy (USD Million)
Figure 12.4 RAS Targeting Therapies Market: Distribution by Route of Administration (USD Million)
Figure 12.5 RAS Targeting Therapies Market: Distribution by Location of Headquarters (USD Million)
Figure 12.6 LUMAKRAS™ (Amgen): Estimated Sales, 2021-2030 (USD Million)
Figure 12.7 Adagrasib (Mirati Therapeutics): Estimated Sales, 2021-2030 (USD Million)
Figure 12.8 AMO-01 (AMO Pharma): Estimated Sales, 2021-2030 (USD Million)
Figure 12.9 Antroquinonol (Golden Biotech): Estimated Sales, 2021-2030 (USD Million)
Figure 12.10 Binimetinib (Array Biopharma): Estimated Sales, 2021-2030 (USD Million)
Figure 12.11 CH7126766/VS6766 (Verastem Oncology): Estimated Sales, 2021-2030 (USD Million)
Figure 12.12 LXH274 (Novartis): Estimated Sales, 2021-2030 (USD Million)
Figure 12.13 Rigosertib (Onconova Therapeutics): Estimated Sales, 2021-2030 (USD Million)
Figure 12.14 RMC-4630 (Revolution Medicine): Estimated Sales, 2021-2030 (USD Million)
Figure 12.15 TG01 (Targovax): Estimated Sales, 2021-2030 (USD Million)
Figure 12.16 Tipifarnib (Kura Oncology): Estimated Sales, 2021-2030 (USD Million)
Figure 12.17 siG12D (Silenseed): Estimated Sales, 2021-2030 (USD Million)
Figure 13.1 RAS Targeting Therapies: Distribution by Target Therapeutic Area
Figure 13.2 RAS Targeting Therapies: Distribution by Type of Molecule and Company Size
Figure 13.3 RAS Targeting Therapies: Distribution by Company Size and Region
Figure 13.4 Most Active Players: Distribution by Number of Products
Figure 13.5 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Status
Figure 13.6 Clinical Trial Analysis: Distribution by Phase of Development, Year and Number of Patients
Figure 13.7 Clinical Trial Analysis: Distribution by Number of Trials, Trial Status and Region
Figure 13.8 Clinical Trial Analysis: Distribution by Primary Purpose
Figure 13.9 Funding and Investment Analysis: Cumulative Number of Funding Instances by Year, 2016-2021
Figure 13.10 Funding and Investment Analysis: Cumulative Amount Invested, 2016-2021 (USD Million)
Figure 13.11 Funding and Investment Analysis: Distribution by Amount Invested and Type of Funding, 2016-2021
Figure 13.12 Funding and Investment Analysis: Distribution of Funding Instances by Geography
Figure 13.13 Funding and Investment Analysis: Distribution by Amount Invested and Type of Funding, 2016-2021
Figure 13.14 Most Active Players: Distribution by Number of Funding Instances, 2016-2021
Figure 13.15 Funding and Investment Analysis: Distribution of Recipient Companies by Year of Establishment and Type of Funding, 2016-2021
Table 4.1 RAS Targeting Therapies: List of Industry and Non-Industry Players
Table 5.1 RAS Targeting Therapies: List of Clinical Trials
Table 8.1 RAS Targeting Therapies: List of Recent Publications
Table 9.1 RAS Targeting Therapies: List of Partnerships and Collaborations
Table 10.1 RAS Targeting Therapies: List of Funding and Investments
The following companies and organizations have been mentioned in the report.
Source 1: www.who.int/news-room/fact-sheets/detail/cancer
Source 2: www.amgenpipeline.com/